NURS 681| QUIZ 6- HEMATOLOGY PHARM
| QUESTIONS AND ANSWERS | UPDATE
RATED A+ | PACE UNIVERSITY 2026/2027
150 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
NURS 681| QUIZ 6- HEMATOLOGY PHARM | QUESTIONS AND ANSWERS | UPDATE RATED A+ | PACE
UNIVERSITY 2026/2027. It contains 150 carefully selected questions that reflect the most current exam content
and testing strategies. Each question is accompanied by a correct answer and a detailed rationale that explains
the underlying pathophysiology, pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 150 Questions
Foundations - Application - NURS 681 6- Hematology Pharm AND Update Rated A PACE University
2026/2027 Hematology Pharmacology Graduate Nurse Practitioner / Advanced Pharmacology
All answers with rationales
,Table of Contents
Content Area Questions Key Topics
Hematopoiesis AND Growth 1-25 Requires, Develops, Agent, Appropriate, Thrombocytopenia
Factors
Anticoagulants AND 26-50 Requires, Appropriate, Thrombocytopenia, Agent, Anticoagulant
Antiplatelet Agents
Thrombolytics AND 51-75 Requires, Appropriate, Thrombocytopenia, Heparin-induced,
Antifibrinolytics Agent
IRON Deficiency Anemia 76-100 Heparin, Requires, Thrombocytopenia, Appropriate, Laboratory
AND IRON Replacement
Vitamin B12 AND Folate 101-125 Appropriate, Thrombocytopenia, Laboratory, Anemia,
Deficiency Anemia Heparin-induced
Sickle CELL Disease AND 126-150 Appropriate, Thrombocytopenia, Requires, Agent,
Hydroxyurea Heparin-induced
TOTAL 150 All questions include answers and detailed rationales
,Section A - Hematopoiesis AND Growth Factors
Q1.
A patient with a mechanical mitral valve requires long-term anticoagulation. Which agent
is preferred and why?
A. Warfarin - irreversible inhibition of vitamin B. Apixaban - direct factor Xa inhibition with
K epoxide reductase, reducing factors II, VII, predictable pharmacokinetics
IX, X
C. Rivaroxaban - once-daily dosing and no D. Dabigatran - direct thrombin inhibition
dietary restrictions with fewer drug interactions
Correct: A - Warfarin - irreversible inhibition of vitamin K epoxide reductase, reducing
factors II, VII, IX, X
Rationale:Mechanical heart valves require vitamin K antagonists like warfarin because
DOACs have not been shown to be safe or effective for this indication. Warfarin irreversibly
inhibits vitamin K epoxide reductase, depleting functional clotting factors. DOACs are
contraindicated in mechanical valves due to increased thromboembolic risk.
Why the other answers are wrong:
B. Apixaban is a DOAC and is contraindicated for mechanical heart valves due to lack of
evidence and increased thrombotic risk.
C. Rivaroxaban, like other DOACs, is not approved for mechanical valve anticoagulation.
D. Dabigatran was specifically studied and found to be inferior to warfarin in mechanical valve
patients, leading to a black-box warning.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 35
Q2.
A patient on heparin develops a 50% drop in platelet count with new thrombosis. Which
test is most specific for confirming the diagnosis?
A. Serotonin release assay (SRA) B. Anti-PF4/heparin ELISA
C. Platelet aggregation test with ADP D. Activated partial thromboplastin time
(aPTT)
Correct: A - Serotonin release assay (SRA)
Rationale:The serotonin release assay (SRA) has the highest specificity for heparin-induced
thrombocytopenia (HIT), using washed platelets and detecting platelet activation in response
to PF4-heparin complexes. Anti-PF4 ELISA is sensitive but less specific. Clinical scoring
(4Ts) and functional assays are used to confirm.
Why the other answers are wrong:
Page 3
, Section A - Hematopoiesis AND Growth Factors
B. Anti-PF4/heparin ELISA is sensitive but has lower specificity and can yield false positives.
C. Platelet aggregation with ADP does not test for HIT-specific antibodies.
D. aPTT monitors heparin effect and is not diagnostic for HIT.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 36
Q3.
Which agent is the recommended antidote for severe bleeding associated with
dabigatran?
A. Protamine sulfate B. Idarucizumab
C. Andexanet alfa D. Vitamin K
Correct: B - Idarucizumab
Rationale:Idarucizumab is a humanized monoclonal antibody fragment that binds dabigatran
with high affinity, reversing its anticoagulant effect. Protamine is used for heparin, and
andexanet alfa is for factor Xa inhibitors. Vitamin K reverses warfarin, not dabigatran.
Why the other answers are wrong:
A. Protamine sulfate neutralizes heparin, not dabigatran.
C. Andexanet alfa reverses factor Xa inhibitors like apixaban and rivaroxaban.
D. Vitamin K is ineffective for direct thrombin inhibitors.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 36
Q4.
A patient with chronic kidney disease (CrCl 25 mL/min) requires anticoagulation for atrial
fibrillation. Which DOAC requires the most significant dose adjustment?
A. Apixaban B. Edoxaban
C. Rivaroxaban D. Dabigatran
Correct: D - Dabigatran
Rationale:Dabigatran is primarily renally excreted (80%) and has the greatest renal
dependence; it is contraindicated in CrCl <30 mL/min. Apixaban, edoxaban, and rivaroxaban
have lower renal clearance and are used with adjustments or caution in this range.
Why the other answers are wrong:
A. Apixaban is only partially renally cleared and can be used with dose adjustment at CrCl 25.
B. Edoxaban requires dose reduction but is not contraindicated at CrCl 25.
C. Rivaroxaban is used with caution but not contraindicated at CrCl 25.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 36
Page 4
| QUESTIONS AND ANSWERS | UPDATE
RATED A+ | PACE UNIVERSITY 2026/2027
150 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
NURS 681| QUIZ 6- HEMATOLOGY PHARM | QUESTIONS AND ANSWERS | UPDATE RATED A+ | PACE
UNIVERSITY 2026/2027. It contains 150 carefully selected questions that reflect the most current exam content
and testing strategies. Each question is accompanied by a correct answer and a detailed rationale that explains
the underlying pathophysiology, pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 150 Questions
Foundations - Application - NURS 681 6- Hematology Pharm AND Update Rated A PACE University
2026/2027 Hematology Pharmacology Graduate Nurse Practitioner / Advanced Pharmacology
All answers with rationales
,Table of Contents
Content Area Questions Key Topics
Hematopoiesis AND Growth 1-25 Requires, Develops, Agent, Appropriate, Thrombocytopenia
Factors
Anticoagulants AND 26-50 Requires, Appropriate, Thrombocytopenia, Agent, Anticoagulant
Antiplatelet Agents
Thrombolytics AND 51-75 Requires, Appropriate, Thrombocytopenia, Heparin-induced,
Antifibrinolytics Agent
IRON Deficiency Anemia 76-100 Heparin, Requires, Thrombocytopenia, Appropriate, Laboratory
AND IRON Replacement
Vitamin B12 AND Folate 101-125 Appropriate, Thrombocytopenia, Laboratory, Anemia,
Deficiency Anemia Heparin-induced
Sickle CELL Disease AND 126-150 Appropriate, Thrombocytopenia, Requires, Agent,
Hydroxyurea Heparin-induced
TOTAL 150 All questions include answers and detailed rationales
,Section A - Hematopoiesis AND Growth Factors
Q1.
A patient with a mechanical mitral valve requires long-term anticoagulation. Which agent
is preferred and why?
A. Warfarin - irreversible inhibition of vitamin B. Apixaban - direct factor Xa inhibition with
K epoxide reductase, reducing factors II, VII, predictable pharmacokinetics
IX, X
C. Rivaroxaban - once-daily dosing and no D. Dabigatran - direct thrombin inhibition
dietary restrictions with fewer drug interactions
Correct: A - Warfarin - irreversible inhibition of vitamin K epoxide reductase, reducing
factors II, VII, IX, X
Rationale:Mechanical heart valves require vitamin K antagonists like warfarin because
DOACs have not been shown to be safe or effective for this indication. Warfarin irreversibly
inhibits vitamin K epoxide reductase, depleting functional clotting factors. DOACs are
contraindicated in mechanical valves due to increased thromboembolic risk.
Why the other answers are wrong:
B. Apixaban is a DOAC and is contraindicated for mechanical heart valves due to lack of
evidence and increased thrombotic risk.
C. Rivaroxaban, like other DOACs, is not approved for mechanical valve anticoagulation.
D. Dabigatran was specifically studied and found to be inferior to warfarin in mechanical valve
patients, leading to a black-box warning.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 35
Q2.
A patient on heparin develops a 50% drop in platelet count with new thrombosis. Which
test is most specific for confirming the diagnosis?
A. Serotonin release assay (SRA) B. Anti-PF4/heparin ELISA
C. Platelet aggregation test with ADP D. Activated partial thromboplastin time
(aPTT)
Correct: A - Serotonin release assay (SRA)
Rationale:The serotonin release assay (SRA) has the highest specificity for heparin-induced
thrombocytopenia (HIT), using washed platelets and detecting platelet activation in response
to PF4-heparin complexes. Anti-PF4 ELISA is sensitive but less specific. Clinical scoring
(4Ts) and functional assays are used to confirm.
Why the other answers are wrong:
Page 3
, Section A - Hematopoiesis AND Growth Factors
B. Anti-PF4/heparin ELISA is sensitive but has lower specificity and can yield false positives.
C. Platelet aggregation with ADP does not test for HIT-specific antibodies.
D. aPTT monitors heparin effect and is not diagnostic for HIT.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 36
Q3.
Which agent is the recommended antidote for severe bleeding associated with
dabigatran?
A. Protamine sulfate B. Idarucizumab
C. Andexanet alfa D. Vitamin K
Correct: B - Idarucizumab
Rationale:Idarucizumab is a humanized monoclonal antibody fragment that binds dabigatran
with high affinity, reversing its anticoagulant effect. Protamine is used for heparin, and
andexanet alfa is for factor Xa inhibitors. Vitamin K reverses warfarin, not dabigatran.
Why the other answers are wrong:
A. Protamine sulfate neutralizes heparin, not dabigatran.
C. Andexanet alfa reverses factor Xa inhibitors like apixaban and rivaroxaban.
D. Vitamin K is ineffective for direct thrombin inhibitors.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 36
Q4.
A patient with chronic kidney disease (CrCl 25 mL/min) requires anticoagulation for atrial
fibrillation. Which DOAC requires the most significant dose adjustment?
A. Apixaban B. Edoxaban
C. Rivaroxaban D. Dabigatran
Correct: D - Dabigatran
Rationale:Dabigatran is primarily renally excreted (80%) and has the greatest renal
dependence; it is contraindicated in CrCl <30 mL/min. Apixaban, edoxaban, and rivaroxaban
have lower renal clearance and are used with adjustments or caution in this range.
Why the other answers are wrong:
A. Apixaban is only partially renally cleared and can be used with dose adjustment at CrCl 25.
B. Edoxaban requires dose reduction but is not contraindicated at CrCl 25.
C. Rivaroxaban is used with caution but not contraindicated at CrCl 25.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 36
Page 4
